{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T20:35:11Z","timestamp":1771014911355,"version":"3.50.1"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1016\/j.jcrs.2012.09.013","type":"journal-article","created":{"date-parts":[[2012,12,4]],"date-time":"2012-12-04T01:14:14Z","timestamp":1354583654000},"page":"158-167","source":"Crossref","is-referenced-by-count":28,"title":["Efficacy and safety of loteprednol etabonate 0.5% gel in the treatment of ocular inflammation and pain after cataract surgery"],"prefix":"10.1097","volume":"39","author":[{"given":"Rajesh K.","family":"Rajpal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence","family":"Roel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raphaele","family":"Siou-Mermet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tara","family":"Erb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-3-20210210","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/00055735-200002000-00002","article-title":"Control of intraocular inflammation associated with cataract surgery.","volume":"11","author":"McColgin","year":"2000","journal-title":"Curr Opin Ophthalmol"},{"key":"R2-3-20210210","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/00055735-200102000-00002","article-title":"Control of intra-ocular inflammation associated with cataract surgery.","volume":"12","author":"El-Harazi","year":"2001","journal-title":"Curr Opin Ophthalmol"},{"key":"R3-3-20210210","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1016\/S0161-6420(98)99054-6","article-title":"A double-masked, placebo-controlled evaluation of 0.5 loteprednol etabonate in the treatment of postoperative inflammation.","volume":"105","year":"1998","journal-title":"Ophthalmology"},{"key":"R5-3-20210210","doi-asserted-by":"crossref","first-page":"835","DOI":"10.3109\/02713688409000796","article-title":"Ocular pressure response to fluorometholone acetate and dexamethasone sodium phosphate.","volume":"3","author":"Stewart","year":"1984","journal-title":"Curr Eye Res"},{"key":"R7-3-20210210","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jcrs.2008.09.024","article-title":", Difluprednate Ophthalmic Emulsion 0.05 (Durezol) Study Group. Difluprednate ophthalmic emulsion 0.05 for postoperative inflammation and pain.","volume":"35","author":"Korenfeld","year":"2009","journal-title":"J Cataract Refract Surg"},{"key":"R8-3-20210210","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/S0886-3350(97)80286-6","article-title":"Control of ocular inflammation after cataract extraction with rimexolone 1 ophthalmic suspension.","volume":"23","author":"Assil","year":"1997","journal-title":"J Cataract Refract Surg"},{"key":"R9-3-20210210","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/S0886-3350(98)80170-3","article-title":"Double-masked, placebo-controlled evaluation of loteprednol etabonate 0.5 for postoperative inflammation; Loteprednol Etabonate Post-Operative Inflammation Study Group 1.","volume":"24","author":"Stewart","year":"1998","journal-title":"J Cataract Refract Surg"},{"key":"R10-3-20210210","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S0002-9394(99)00034-3","article-title":"Controlled evaluation of loteprednol etabonate and prednisolone acetate in the treatment of acute anterior uveitis.","volume":"127","year":"1999","journal-title":"Am J Ophthalmol"},{"key":"R11-3-20210210","first-page":"31","article-title":"A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis.","volume":"23","author":"Asbell","year":"1997","journal-title":"CLAO J"},{"key":"R12-3-20210210","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0091-6749(98)70094-6","article-title":"A randomized, double-masked, placebo-controlled parallel study of 0.2 loteprednol etabonate in patients with seasonal allergic conjunctivitis.","volume":"102","author":"Dell","year":"1998","journal-title":"J Allergy Clin Immunol"},{"key":"R13-3-20210210","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1089\/jop.2010.0085","article-title":"Topical loteprednol pretreatment reduces cyclosporine stinging in chronic dry eye disease.","volume":"27","author":"Sheppard","year":"2010","journal-title":"J Ocul Pharmacol Ther"},{"key":"R14-3-20210210","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1136\/bjo.2007.132621","article-title":"Treatment of ocular inflammatory conditions with loteprednol etabonate.","volume":"92","author":"Pavesio","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"R17-3-20210210","doi-asserted-by":"crossref","first-page":"933","DOI":"10.3109\/02713689109020329","article-title":"Ocular absorption and distribution of loteprednol etabonate, a soft steroid, in rabbit eyes.","volume":"10","author":"Druzgala","year":"1991","journal-title":"Curr Eye Res"},{"key":"R18-3-20210210","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1177\/112067219800800105","article-title":"The effects of Rimexolone 1 in postoperative inflammation after cataract extraction. A double-masked placebo-controlled study.","volume":"8","author":"Bron","year":"1998","journal-title":"Eur J Ophthalmol"},{"key":"R19-3-20210210","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1442-9071.2004.00782.x","article-title":"Corneal epithelial cellular dysfunction from benzalkonium chloride (BAC) in vitro.","volume":"32","author":"Cha","year":"2004","journal-title":"Clin Exp Ophthalmol"},{"key":"R20-3-20210210","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1076\/0271-3683(200002)2021-DFT085","article-title":"Toxicity of preserved and unpreserved antiglaucoma topical drugs in an in vitro model of conjunctival cells.","volume":"20","author":"De Saint Jean","year":"2000","journal-title":"Curr Eye Res"}],"container-title":["Journal of Cataract and Refractive Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0886335012013788?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0886335012013788?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/10.1016\/j.jcrs.2012.09.013","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T17:05:52Z","timestamp":1620925552000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/02158034-201302000-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2]]},"references-count":16,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1016\/j.jcrs.2012.09.013","relation":{},"ISSN":["0886-3350"],"issn-type":[{"value":"0886-3350","type":"print"}],"subject":[],"published":{"date-parts":[[2013,2]]}}}